Reimbursement Review Reports


( Last Updated : August 1, 2021)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

 

Brand Name Sort descending Generic name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Abraxane Nab-paclitaxel Metastatic Pancreatic Cancer Reimburse with clinical criteria and/or conditions Complete Feb 14, 2014 Sep 23, 2014
Adcetris Brentuximab Vedotin Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) Reimburse with clinical criteria and/or conditions Complete Apr 2, 2020 Dec 3, 2020
Adcetris Brentuximab vedotin Systemic Anaplastic Large Cell Lymphoma Reimburse with clinical criteria and/or conditions Complete Mar 15, 2013 Dec 5, 2013
Adcetris Brentuximab Vedotin HL at high risk of relapse or progression post-ASCT Reimburse with clinical criteria and/or conditions Complete Aug 10, 2017 Feb 21, 2018
Adcetris Brentuximab Vedotin Primary cutaneous anaplastic large cell Lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) Reimburse with clinical criteria and/or conditions Complete Mar 30, 2020 Dec 3, 2020
Adcetris Brentuximab vedotin Withdrawn Apr 5, 2016
Adcetris Brentuximab Vedotin peripheral T-cell lymphoma (PTCL) Reimburse Complete Oct 8, 2019 Jun 4, 2020
Adcetris Brentuximab vedotin Hodgkin Lymphoma Reimburse with clinical criteria and/or conditions Complete Mar 14, 2013 Aug 29, 2013
Adcetris (Resubmission) Brentuximab Vedotin Hodgkin lymphoma (HL) Do not reimburse Complete Aug 27, 2018 Mar 7, 2019
Afinitor Everolimus Pancreatic Neuroendocrine Tumour Reimburse with clinical criteria and/or conditions Complete Feb 27, 2012 Aug 30, 2012